Pancreatic Cancer Research

ResearcherOntario Institute for Cancer ResearchActive in the last 2 years

Spring Holter

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5103538329. Sources: OpenAlex.

Their work

Papers
22 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
104
Papers, trials and grants by year

2012: 3 papers · 2013: 1 paper · 2014: 1 paper · 2015: 2 papers · 2016: 1 paper · 2017: none · 2018: 3 papers · 2019: 1 paper · 2020: 1 paper · 2021: 3 papers · 2022: 2 papers · 2023: none · 2024: none · 2025: 3 papers · 2026: 1 paper

Papers 22

  1. Extra-lineage tissue programs define the transcription states of human pancreatic cancer Co-author DOI 10.64898/2026.04.29.721655↗
  2. Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial. Co-author DOI 10.1038/s41467-025-60808-z↗
  3. The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer. Co-author DOI 10.1038/s41698-025-00888-8↗
  4. The subclonal footprint of pervasive early dissemination in pancreatic cancer Co-author DOI 10.1101/2025.11.27.690823↗
  5. Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detectio… Co-author DOI 10.1016/j.gie.2021.10.025↗
  6. Is Biannual Surveillance for Pancreatic Cancer Sufficient in Individuals With Genetic Syndromes or Familial Pancreatic Cancer? Co-author DOI 10.6004/jnccn.2021.7107↗
  7. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2021.01.220↗
  8. Recommendations for a More Organized and Effective Approach to the Early Detection of Pancreatic Cancer From the PRECEDE (Pancreatic Cancer Early Detection) Co… Co-author DOI 10.1053/j.gastro.2021.08.036↗
  9. Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma. Co-author DOI 10.1136/gutjnl-2020-320730↗
  10. A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination-deficient Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-1439↗
  11. A region-based gene association study combined with a leave-one-out sensitivity analysis identifies SMG1 as a pancreatic cancer susceptibility gene. Co-author DOI 10.1371/journal.pgen.1008344↗
  12. Comparison of Practice Guidelines, BRCAPRO, and Genetic Counselor Estimates to Identify Germline BRCA1 and BRCA2 Mutations in Pancreatic Cancer. First author DOI 10.1007/s10897-018-0212-1↗
  13. Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. Co-author DOI 10.1158/1078-0432.ccr-17-2994↗
  14. Reflex Testing for Germline BRCA1, BRCA2, PALB2, and ATM Mutations in Pancreatic Cancer: Mutation Prevalence and Clinical Outcomes From Two Canadian Research R… Co-author DOI 10.1200/po.17.00098↗
  15. Candidate DNA repair susceptibility genes identified by exome sequencing in high-risk pancreatic cancer. Co-author DOI 10.1016/j.canlet.2015.10.030↗
  16. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Co-author DOI 10.1053/j.gastro.2014.11.042↗
  17. Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma. Co-author DOI 10.1200/jco.2014.59.7401↗
  18. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Co-author DOI 10.1038/bjc.2014.418↗
  19. Exome sequencing identifies nonsegregating nonsense ATM and PALB2 variants in familial pancreatic cancer. Co-author DOI 10.1186/1479-7364-7-11↗
  20. Moderators of cancer-related distress and worry after a pancreatic cancer genetic counseling and screening intervention. Co-author DOI 10.1002/pon.2026↗
  21. Identification of germline genomic copy number variation in familial pancreatic cancer. Co-author DOI 10.1007/s00439-012-1183-1↗
  22. Screening for pancreatic cancer in a high-risk cohort: an eight-year experience. Co-author DOI 10.1007/s11605-011-1781-6↗

Closest collaborators

The 25 strongest of 104 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Steve Gallinger · 21 shared papers, 2012–2026 · strength 1.69
  2. Robert C. Grant · 15 shared papers, 2012–2026 · strength 1.39
  3. George Zogopoulos · 13 shared papers, 2012–2025 · strength 1.23
  4. Jennifer Jane Knox · 10 shared papers, 2018–2026 · strength 1.19
  5. Ayelet Borgida · 16 shared papers, 2012–2026 · strength 1.19
  6. Grainne Mary O'Kane · 9 shared papers, 2018–2026 · strength 1.11
  7. Faiyaz Notta · 7 shared papers, 2018–2026 · strength 0.93
  8. Yifan Wang · 7 shared papers, 2019–2025 · strength 0.77
  9. Sandra Elisabeth Fischer · 7 shared papers, 2018–2025 · strength 0.75
  10. Michelle Chan‐Seng‐Yue · 5 shared papers, 2016–2026 · strength 0.73
  11. Erica S. Tsang · 4 shared papers, 2025–2026 · strength 0.69
  12. Malcolm J. Moore · 6 shared papers, 2012–2025 · strength 0.49
  13. Raymond Jang · 3 shared papers, 2021–2025 · strength 0.42
  14. Kyaw Lwin Aung · 3 shared papers, 2018–2025 · strength 0.38
  15. Yuanchang Fang · 2 shared papers, 2025–2026 · strength 0.36
  16. Eugenia Flores Figueroa · 2 shared papers, 2025–2026 · strength 0.36
  17. David F. Schaeffer · 3 shared papers, 2021–2025 · strength 0.36
  18. Daniel John Renouf · 3 shared papers, 2021–2025 · strength 0.36
  19. Barbara T. Grünwald · 2 shared papers, 2025 · strength 0.33
  20. Talia Golan · 4 shared papers, 2014–2021 · strength 0.28
  21. Joanna M. Karasinska · 2 shared papers, 2021–2025 · strength 0.27
  22. James Thomas Topham · 2 shared papers, 2021–2025 · strength 0.27
  23. David William Hedley · 4 shared papers, 2014–2018 · strength 0.22
  24. Ashton Anthony Connor · 4 shared papers, 2015–2018 · strength 0.20
  25. Masoom A. Haider · 2 shared papers, 2012–2025 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.